PubMed-compiled information sheet
This sheet was compiled from PubMed (NIH) abstracts using AI assistance. Every factual claim is cited to a real PubMed article (see the source list). It has not yet been human-reviewed — confirm with a healthcare provider before use.
Compiled from 30 PubMed articles · model: gemma4:31b
Summary
Background
Traditional uses
Active compounds
Mechanism of action
Clinical evidence
Pyrrosia lingua alleviates nephrolithiasis in rat models by reducing renal oxalic acid and calcium concentrations [PMID:35104754, 30200732]
Ethanolic extract of P. lingua inhibited trabecular bone loss and weight gain in ovariectomized mice [PMID:35033946]
Shi Wei Ru Xiang pill suppressed NLRP3 inflammasome activation and attenuated ankle swelling in rat models [PMID:40635741]
Caffeoylquinic acid compounds from P. lingua synergistically enhance the antibacterial activity of levofloxacin against UPEC strains [PMID:39683837]
P. lingua showed anti-SARS-CoV effects in tests of 200 Chinese herbal extracts [PMID:33155905, 33037698]
Drug interactions
Evidence summary
PubMed sources
- 1.PMID: 35033946 (2022) — Ethanolic extract of Pyrrosia lingua (Thunb.) Farw. ameliorates OVX-induced bone loss and RANKL-induced osteoclastogenesis. · Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
- 2.PMID: 40635741 (2025) — Shi Wei Ru Xiang pill alleviates acute gouty arthritis through suppressing NLRP3 inflammasome activation. · Frontiers in pharmacology
- 3.PMID: 39683837 (2024) — Synergistic Effects of Pyrrosia lingua Caffeoylquinic Acid Compounds with Levofloxacin Against Uropathogenic Escherichia coli: Insights from Molecular Dynamics Simulations, Antibiofilm, and Antimicrobial Assessments. · Molecules (Basel, Switzerland)
- 4.PMID: 35104754 (2022) — Molecular mechanism of Pyrrosia lingua in the treatment of nephrolithiasis: Network pharmacology analysis and in vivo experimental verification. · Phytomedicine : international journal of phytotherapy and phytopharmacology
- 5.PMID: 30200732